Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bacterial topoisomerase inhibitors - Redx Pharma

Next Previous
Search
Drug Profile

Research programme: bacterial topoisomerase inhibitors - Redx Pharma

Alternative Names: NBTIs; NTTI; REDX06213; REDX06276; REDX07623; REDX08106

Latest Information Update: 18 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Redx Pharma
  • Class Antibacterials; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Bacterial infections

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 18 Sep 2023 Research programme: bacterial topoisomerase inhibitors - Redx Pharma is available for licensing as of 31 Jan 2019. https://www.redxpharma.com/wp-content/uploads/2020/12/Deinove-return-rights-to-Redxs-Anti-infective-Programme.pdf
  • 18 Sep 2023 Discontinued - Preclinical for Bacterial infections in United Kingdom (IV)
  • 28 Jul 2020 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top